Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Ling Ying Lu; Po Hao Feng; Ming Sun Yu; Min Chi Chen; Alex Jia Hong Lin; Justin L. Chen; Lennex Hsueh Lin Yu

doi:10.1016/j.cytogfr.2022.01.001

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Ling Ying Lu, Po Hao Feng, Ming Sun Yu, Min Chi Chen, Alex Jia Hong Lin, Justin L. Chen, Lennex Hsueh Lin Yu

Research output: Contribution to journal › Short survey › peer-review

15 Citations (Scopus)

Abstract

Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.

Original language	English
Pages (from-to)	34-43
Number of pages	10
Journal	Cytokine and Growth Factor Reviews
Volume	63
DOIs	https://doi.org/10.1016/j.cytogfr.2022.01.001
Publication status	Published - Feb 2022

Keywords

Coronavirus disease 2019
COVID-19
Interferon alpha
SARS‑CoV‑2
Severe acute respiratory syndrome coronavirus 2

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Immunology and Allergy
Immunology
General Biochemistry,Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cytogfr.2022.01.001

Cite this

@article{4a19514f50f448fb8da6cb0d631ff85c,

title = "Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review",

abstract = "Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.",

keywords = "Coronavirus disease 2019, COVID-19, Interferon alpha, SARS‑CoV‑2, Severe acute respiratory syndrome coronavirus 2",

author = "Lu, {Ling Ying} and Feng, {Po Hao} and Yu, {Ming Sun} and Chen, {Min Chi} and Lin, {Alex Jia Hong} and Chen, {Justin L.} and Yu, {Lennex Hsueh Lin}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = feb,

doi = "10.1016/j.cytogfr.2022.01.001",

language = "English",

volume = "63",

pages = "34--43",

journal = "Cytokine and Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Current utilization of interferon alpha for the treatment of coronavirus disease 2019

T2 - A comprehensive review

AU - Lu, Ling Ying

AU - Feng, Po Hao

AU - Yu, Ming Sun

AU - Chen, Min Chi

AU - Lin, Alex Jia Hong

AU - Chen, Justin L.

AU - Yu, Lennex Hsueh Lin

PY - 2022/2

Y1 - 2022/2

N2 - Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.

AB - Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.

KW - Coronavirus disease 2019

KW - COVID-19

KW - Interferon alpha

KW - SARS‑CoV‑2

KW - Severe acute respiratory syndrome coronavirus 2

UR - http://www.scopus.com/inward/record.url?scp=85123864356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123864356&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2022.01.001

DO - 10.1016/j.cytogfr.2022.01.001

M3 - Short survey

C2 - 35115233

AN - SCOPUS:85123864356

SN - 1359-6101

VL - 63

SP - 34

EP - 43

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

ER -

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this